ES2791251T3 - Péptidos de Ledgf y formulaciones de los mismos para el tratamiento de trastornos degenerativos - Google Patents

Péptidos de Ledgf y formulaciones de los mismos para el tratamiento de trastornos degenerativos Download PDF

Info

Publication number
ES2791251T3
ES2791251T3 ES13794410T ES13794410T ES2791251T3 ES 2791251 T3 ES2791251 T3 ES 2791251T3 ES 13794410 T ES13794410 T ES 13794410T ES 13794410 T ES13794410 T ES 13794410T ES 2791251 T3 ES2791251 T3 ES 2791251T3
Authority
ES
Spain
Prior art keywords
ledgf
peptide
composition
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13794410T
Other languages
English (en)
Spanish (es)
Inventor
Uday Kompella
Rinku Baid
Arun Upadhyay
Sarath Yandrapu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
University of Colorado Colorado Springs
Original Assignee
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/065620 external-priority patent/WO2013074988A1/en
Application filed by University of Colorado System, University of Colorado Colorado Springs filed Critical University of Colorado System
Application granted granted Critical
Publication of ES2791251T3 publication Critical patent/ES2791251T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
ES13794410T 2012-05-21 2013-05-21 Péptidos de Ledgf y formulaciones de los mismos para el tratamiento de trastornos degenerativos Active ES2791251T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649847P 2012-05-21 2012-05-21
PCT/US2012/065620 WO2013074988A1 (en) 2011-11-17 2012-11-16 Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
PCT/US2013/042074 WO2013177198A1 (en) 2012-05-21 2013-05-21 Ledgf peptides and formulations thereof for treatment of degenerative disorders

Publications (1)

Publication Number Publication Date
ES2791251T3 true ES2791251T3 (es) 2020-11-03

Family

ID=49624295

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13794410T Active ES2791251T3 (es) 2012-05-21 2013-05-21 Péptidos de Ledgf y formulaciones de los mismos para el tratamiento de trastornos degenerativos

Country Status (12)

Country Link
US (2) US9526760B2 (https=)
EP (1) EP2852399B1 (https=)
JP (2) JP6632376B2 (https=)
CN (2) CN110054677A (https=)
AU (1) AU2013266468B2 (https=)
BR (1) BR112014028951A8 (https=)
CA (1) CA2873771A1 (https=)
DK (1) DK2852399T3 (https=)
ES (1) ES2791251T3 (https=)
IN (1) IN2014MN02461A (https=)
RU (1) RU2617964C2 (https=)
WO (1) WO2013177198A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014028951A8 (pt) * 2012-05-21 2021-09-14 Univ Colorado Regents Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
JP7549575B2 (ja) * 2018-06-22 2024-09-11 ビオラリクス ベー．フェー． 経口投与用生物学的ポリマーの製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221787A (en) 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4469689A (en) 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US6750052B1 (en) 1997-07-23 2004-06-15 The Brigham And Women's Hospital, Inc. Lens epithelial cell derived growth factor
US7708915B2 (en) * 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040157810A1 (en) 2002-08-23 2004-08-12 Teicher Martin H. Corticosteroid conjugates and uses thereof
US7514233B2 (en) 2002-09-26 2009-04-07 K.U. Leuven Research & Development Integrase cofactor
US20040253606A1 (en) * 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20060166879A1 (en) 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
EP1774043A4 (en) * 2004-05-28 2009-09-02 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
EP1971288B1 (en) 2005-12-30 2013-02-13 Neurotech USA, Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
EP2520935A3 (en) * 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2008053478A2 (en) * 2006-10-30 2008-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
US8168393B2 (en) * 2007-02-16 2012-05-01 The Brigham And Women's Hospital, Inc. Compositions and methods for diagnosing tumors using LEDGF/p75
AU2009262670B2 (en) * 2008-06-26 2013-06-20 Zevra Denmark A/S Use of Hsp70 as a regulator of enzymatic activity
GB0812742D0 (en) * 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US10234453B2 (en) * 2011-07-01 2019-03-19 Inova Diagnostics, Inc. Method for increasing specificity of diagnostic tests for autoimmune diseases
BR112014028951A8 (pt) * 2012-05-21 2021-09-14 Univ Colorado Regents Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor

Also Published As

Publication number Publication date
CN104470534A (zh) 2015-03-25
CA2873771A1 (en) 2013-11-28
AU2013266468A1 (en) 2014-12-18
US10221226B2 (en) 2019-03-05
AU2013266468B2 (en) 2017-11-09
JP2015519343A (ja) 2015-07-09
BR112014028951A8 (pt) 2021-09-14
JP2018172386A (ja) 2018-11-08
CN110054677A (zh) 2019-07-26
BR112014028951A2 (pt) 2017-07-25
US20170129929A1 (en) 2017-05-11
US20150147404A1 (en) 2015-05-28
IN2014MN02461A (https=) 2015-07-10
WO2013177198A1 (en) 2013-11-28
RU2617964C2 (ru) 2017-04-28
JP6632376B2 (ja) 2020-01-22
EP2852399A1 (en) 2015-04-01
RU2014151603A (ru) 2016-07-10
US9526760B2 (en) 2016-12-27
EP2852399A4 (en) 2016-03-23
DK2852399T3 (da) 2020-05-04
EP2852399B1 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
Liu et al. Penetratin, a potentially powerful absorption enhancer for noninvasive intraocular drug delivery
TWI720051B (zh) 經修飾之介白素－７融合蛋白的調配物
ES2644016T3 (es) Péptidos para su uso en el tratamiento tópico de enfermedades neurodegenerativas retinianas, en particular en estadios tempranos de retinopatía diabética y otras enfermedades retinianas en las que la neurodegeneración desempeña un papel esencial
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
EP3452075B1 (en) Ophthalmic pharmaceutical composition
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
JP6884755B2 (ja) ペプチド組成物および使用方法
ES2791251T3 (es) Péptidos de Ledgf y formulaciones de los mismos para el tratamiento de trastornos degenerativos
CN116570706A (zh) 使用多肽治疗白内障的方法
US11207423B2 (en) Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs
WO2013005603A9 (ja) 結膜におけるアレルギー性炎症の予防及び／又は治療剤
AU2020419590A1 (en) Stable formulations of silk-derived protein
CN114073774A (zh) 药物和野生型穿膜肽衍生物的组合物
CN118206667A (zh) 一种脂质化修饰抗血管生成多肽、纳米胶束、温敏性水凝胶及制备方法和应用
EP3402504A1 (en) Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa
WO2026026844A1 (zh) 一种两亲性药物载体及其在眼部药物递送中的应用
EP4475866A1 (en) Peptides and methods of use thereof in treating ocular disorders
Mackay et al. Treatment of the Cornea Using Transcytotic Delivery into the Tear Film
JP2023517459A (ja) 眼科用医薬組成物及びその使用
Baid Lens epithelium derived growth factor (1-326): a new protein drug for retinal diseases
Tyagi A novel protein drug, suprachoroidal delivery, and protein sustained release systems for choroidal neovascularization